October 05, 2016 – Here, we make available to our readers a Drug Safety Communication by the American Food & Drug Administration (FDA), where FDA warns about the risk of hepatitis B virus (HBV) reactivation in some patients treated with …

FDA warns about the risk of HBV reactivation in patients treated with DAA for HCV-infection Read more »

March 11, 2016 – Medscape Multispeciality just published  a CDC Expert Commentary by John W. Ward, MD, Director, Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, which addresses the double sided sword of the coming to market of …

Extraorbitant cost keeps HCV care out of reach for many patients: Are there profound ethical and societal issues looming? Read more »

Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, …

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Read more »

April 4, 2015 – There’s nothing like the real world to shed light on the safety of new drugs and devices. Clinical trials may be the best way to compare treatments, but patients enrolled in trials are carefully selected and …

Could the HCV drug sofosbuvir be cardiotoxic? Is there a role in genetic predisposition? Read more »

July 09, 2014 – A very exiting review article in the British Medical Journal (BMJ) on July 07, 2014 discusses the newest developments in the treatment options in HCV infection. This is an excerpt from the article, which can be …

Newest developments in antiviral treatment options in hepatitis C virus infection (HCV) Read more »